Stimulant actions in rodents: Implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse

被引:104
作者
Kuczenski, R [1 ]
Segal, DS [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA
关键词
attention-cleficit/hyperactivity disorder; stimulants; substance abuse; methylphenidate; childhood disorders;
D O I
10.1016/j.biopsych.2004.12.036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Most evidence supports the continued use of stimulants as the best available pharmacotherapy the treatment of children with attention-deficit/hyperactivity disorder (ADHD), but little is known about possible enduring behavioral and neuroadaptational consequences of long-term stimulant exposure. Although a variety of preclinical studies, particularly, those using methylphenidate (MP), have attempted to address these issues, most of these studies have used procedures that might not adequately simulate clinical treatment conditions, and results have not been entirely consistent. In particular, the rationale for selection of MP doses that simulate clinical exposure has not been well defined. We suggest that the use of more appropriate treatment conditions, including doses that result in plasma drug levels comparable to therapeutic levels, will provide a more accurate model for adequately assessing the therapeutic mechanisms and potential long-term consequences of stimulant psychotherapy in the treatment of ADHD.
引用
收藏
页码:1391 / 1396
页数:6
相关论文
共 87 条
[31]  
Hale TS, 2000, MENT RETARD DEV D R, V6, P214, DOI 10.1002/1098-2779(2000)6:3<214::AID-MRDD9>3.0.CO
[32]  
2-M
[33]   Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine [J].
Izenwasser, S ;
Coy, AE ;
Ladenheim, B ;
Loeloff, RJ ;
Cadet, JL ;
French, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 373 (2-3) :187-193
[34]   KINETICS OF COCAINE IN HUMANS AFTER INTRAVENOUS AND INTRANASAL ADMINISTRATION [J].
JAVAID, JI ;
MUSA, MN ;
FISCHMAN, M ;
SCHUSTER, CR ;
DAVIS, JM .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1983, 4 (01) :9-18
[35]   Pharmacokinetics and clinical effectiveness of methylphenidate [J].
Kimko, HC ;
Cross, JT ;
Abernethy, DR .
CLINICAL PHARMACOKINETICS, 1999, 37 (06) :457-470
[36]  
Kuczenski R, 2002, J NEUROSCI, V22, P7264
[37]  
Kuczenski R, 2001, J PHARMACOL EXP THER, V296, P876
[38]   Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models [J].
Laviola, G ;
Adriani, W ;
Terranova, ML ;
Gerra, G .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1999, 23 (07) :993-1010
[39]   A COMPARISON OF THE MOTOR-ACTIVATING EFFECTS OF ACUTE AND CHRONIC EXPOSURE TO AMPHETAMINE AND METHYLPHENIDATE [J].
MCNAMARA, CG ;
DAVIDSON, ES ;
SCHENK, S .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 45 (03) :729-732
[40]  
Mehta MA, 2000, J NEUROSCI, V20